Biosphincter to treat fecal incontinence. Phase 1/2 clinical trial. Sbir phase IIB
Ended Project Grant Awarded Last action
- Award ID
- R44DK105593
- Recipient
-
Cellf-Bio Inc. UEI DQMVZJFCVNK3
- Awarding agency
-
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $7,220,134
Award facts
- Assistance listing
- 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research
- Completion date
- Originally
- Funding
-
- $5,826,508.00 Federal
- $1,393,626.00 Non-federal
- Place of performance
- Virginia, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $1,393,626 | $0 | |
| Amendment | $1,393,626 | $1,393,626 | |
| Amendment | $0 | $0 | |
| Amendment | $1,393,626 | $0 | |
| Amendment | $360,815 | $0 | |
| Original award | $1,284,815 | $0 |
Show all 14
Quick answers
Who received award R44DK105593?
R44DK105593 was awarded to Cellf-Bio Inc. by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on September 23, 2015.
How much is award R44DK105593 worth?
$7,220,134 has been obligated on R44DK105593: $5,826,508 in federal funding and $1,393,626 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award